|
|
|
|
|
|
Sponsors and Collaborators: |
University of California, San Francisco Juvenile Diabetes Research Foundation |
Information provided by: | University of California, San Francisco |
ClinicalTrials.gov Identifier: | NCT00501709 |
Pancreatic islets are the part of the pancreas that produce insulin and help control the blood sugar. This study aims to improve islet transplantation as atreatment for Type 1 Diabetes by using a new combination of immunosuppressive drugs that have been successful in treating other autoimmune diseases and in preventing kidney transplant rejection.
Condition | Intervention | Phase |
Type 1 Diabetes |
Drug: Raptiva |
Phase I Phase II |
MedlinePlus related topics: | Diabetes Diabetes Type 1 |
Drug Information available for: | Insulin Efalizumab |
Study Type: | Interventional |
Study Design: | Open Label, Uncontrolled, Single Group Assignment |
Ages Eligible for Study: | 18 Years to 75 Years |
Genders Eligible for Study: | Both |
Inclusion Criteria:
Progressive secondary complications as defined by
Exclusion Criteria:
Contact: Joan Mcelroy, RN | 415-353-8893 | islettransplant@surgery.ucsf.edu |
Contact: Tara Rojas | 415-353-1170 | rojast@surgery.ucsf.edu |
United States, California | |||||
University of California, San Francisco | Recruiting | ||||
San Francisco, California, United States, 94143 |
University of California, San Francisco |
Juvenile Diabetes Research Foundation |
Principal Investigator: | Peter G Stock, M.D., Ph.D. | University of California, San Francisco |
Principal Investigator: | Andrew Posselt, M.D., Ph.D. | University of California, San Francisco |
Study ID Numbers: | 39-42C |
First Received: | July 12, 2007 |
Last Updated: | May 5, 2008 |
ClinicalTrials.gov Identifier: | NCT00501709 |
Health Authority: | United States: Food and Drug Administration |
|
|
|